

Evaluation of extracts obtained from marine by-products using eutectic solvent systems for their therapeutic application in the dry eye disease


Maha M. Abdallah a,b *, Amalia Enríquez-de-Salamanca c,d, Yolanda Diebold c,d, Maria González-García ^{c,d}, Ana A. Matias ^b, Maria R. Bronze ^{a,b,e}, Naiara Fernández ^b

a Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, 2780-157 Oeiras, Portugal; biBET, Instituto de Biologia Experimental e Tecnológica, 2781-901 Oeiras, Portugal; c Institute of Applied Ophthalmobiology (IOBA), University of Valladolid, 47011 Valladolid, Spain; d Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 28029, Madrid, Spain; e Faculdade de Farmácia da Universidade de Lisboa (FFUL), 1649-003 Lisbon, Portugal


* maha.abdallah@ibet.pt

INTRODUCTION


Hyaluronic acid (HA) is used in the treatment of the dry eye disease (DED) as it has shown improvements in the corneal epithelial barrier. In this work, HA is extracted from the marine by-product tuna vitreous humor (VH) using natural deep eutectic solvents (NADES) to replace toxic and costly conventional extractions. These solvents are prepared using molecules such as lactic acid, fructose and urea, and are used to extract HA from VH at specific conditions. The obtained isolated extract and the mixture of extract solved in the NADES are evaluated for their potential application in the treatment of the DED.



METHODS



RESULTS – Extract obtained using lactic acid-based NADES



+++P < 0.001. Statistical analysis → SPSS software used for one-way analysis of variance (ANOVA) and Tukey's post hoc test or Games-Howell test for intergroup comparisons with n=3.

CONCLUSION

HA extraction from VH is done using green and novel NADES, as they have shown to be optimal in its isolation. The extracts, along with the mixture of the extract with the NADES have shown to have a therapeutic effect. Therefore, these compounds could be studied for their potential application in the treatment of the DED.

ACKNOWLEDGMENTS: The project IT-DED³ is funded by the European Union's H2020 -MSCA program. Grant agreement: 765608. iNOVA4Health – UIDB/04462/2020 and UIDP/04462/2020, a program financially supported by Fundação para a Ciência e Tecnologia / Ministério da Ciência, Tecnologia e Ensino Superior, through national funds and funding from INTERFACE Programme, through the Innovation, Technology and Circular Economy Fund (FITEC), are acknowledged.

Financiado por: FITEC Fundo de Inovação, Tecnologia e Economia Circular







